Oncolytics Biotech Inc T.ONC

ONCY's pelareorep upregulates PD-(L)1 / PD-L2

[Noteable]

 

Reolysin (pelareorep) upregulates PD-L2 expression in a manner that mirrored PD-L1, albeit to a lesser extent than PD-L1 induction.

https://go.gale.com/ps/i.do?p=AONE&u=googlescholar&id=GALE|A522178859&v=2.1&it=r&sid=googleScholar&asid=1149bf24

Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer

The majority of colorectal cancers (CRCs) are microsatellite stable (MSS) and resistant to immunotherapy.

MSS tumors that account for 85% of all CRC can be effectively converted to immunotherapy-sensitive cancers by introducing reovirus to the therapeutic regimen. Our data confidently establishes that reovirus sensitizes MSS tumors to anti-PD-1 therapy via increasing the expression of PD-L1 marker on respective target cells. The combinatorial treatment has successfully immune populated the MSS tumor TME in all three study models. Immunotherapy, which has achieved phenomenal success in many cancer types, may now be successfully implemented in MSS ‘cold’ or immunosuppressive CRC tumors, and provides a rationale to extend combination reovirus-ICI therapy into clinical testing.

https://www.frontiersin.org/articles/10.3389/fonc.2022.1018767/full

[Proboscises]

Thanks to Noteable for highlighting this impressive trial conducted by multiple scientists at numerous respected institutions. The trial was funded by the NIH and none of the contributors had conflicts of interest. They procured the reovirus they used from Oncolytics Biotech.  Gastro-intestinal cancers like colo-rectal cancer and pancreatic cancer are considered "cold" cancers

[Noteable]

https://stockhouse.com/companies/bullboard?symbol=oncy&postid=36289094

[Noteable]

Also - upregulated levels of PD-L1 (High-PD-L1) are associated with high levels of tumor infilitrating lymphocytes (TiLs) and stem cell markers which in turm serve to remodel an immunosupressive TME found surrounding cancer cells, and which contributes to a cancer cell's growth and spread.

[pelaboost]

@Noteable. I have been thinking about this for a while from my lay perspective. Cost of treatment is increasingly a concern. Is it possible that pelareorep and a PD-L1 could stand in for ADCs in some instances. TIA

[Noteable]

In metastatic breast cancer for example, certain patients cannot tolerate, do not respond, or quickly relapse on ADC therapy. In these instances a combination of pelareiorep + immune checkpoint inhibitor + chemotherapy could very well be indicated. It is for this reason that ONCY's CMO Thomas Heineman finally announced that ONCY will be targeting early mBC patients with pelareorep in a

[Noteable]

Inside tumors, cancer stem cells can proliferate into new cancerous tissue. These cells are metastatic, resistant to chemotherapy, and extremely skilled at hiding from the immune system to avoid attack. “They are the root of the tumor,” said Bruno Sainz Jr., a molecular oncologist at the Sols-Morreale Biomedical Research Institute (IIBM) in Madrid Spain. “If you are able to attack and